Effects of fenofibrate and simvastatin on HDL-related biomarkers in low-HDL patients

Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944 · see citing works

Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)

Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011 · see citing works

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial

(2002) · The Lancet · doi:10.1016/s0140-6736(02)09327-3 · Cited by 6,992 · see citing works

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

(2005) · The Lancet · doi:10.1016/s0140-6736(05)67667-2 · Cited by 3,284 · see citing works

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

Brown, B. G., Zhao, X.-Q., Chait, A., Fisher, L. D., Cheung, M. C., Morse, J. S., Dowdy, A. A., Marino, E. K., Bolson, E. L., Alaupovic, P., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011090 · Cited by 1,979 · see citing works

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR**STELLAR = Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin. Trial)

Jones, P. H., Davidson, M. H., Stein, E. A., Bays, H. E., McKenney, J. M., Miller, E., Cain, V. A., & Blasetto, J. W. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00530-7 · Cited by 1,392 · see citing works

Secondary Prevention by Raising HDL Cholesterol and Reducing Triglycerides in Patients With Coronary Artery Disease: The Bezafibrate Infarction Prevention (BIP) Study

(2000) · Circulation · doi:10.1161/01.cir.102.1.21 · Cited by 1,273 · see citing works

Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention1European Society of Cardiology, European Atherosclerosis Society, European Society of Hypertension, International Society of Behavioural Medicine, European Society of General Practice/Family Medicine, European Heart Network.1,2Published simultaneously in the European Heart Journal 1998;19:1434–1503 and the Journal of Hypertension (Summary only) 1998;16(10).2

Wood, D., Backer, G. D., Færgeman, O., Graham, I. D., Mancia, G., & Pyörälà, K. (1998) · Atherosclerosis · doi:10.1016/s0021-9150(98)90209-x · Cited by 1,251 · see citing works

Relation of Gemfibrozil Treatment and Lipid Levels With Major Coronary Events

Robins, S. J., Collins, D. E., Wittes, J. T., Papademetriou, V., DEEDWANIA, P. C., Schaefer, E. J., McNamara, J. R., Kashyap, M. L., Hershman, J. M., WEXLER, L. F., et al. (2001) · JAMA · doi:10.1001/jama.285.12.1585 · Cited by 916 · see citing works

Diabetes, Plasma Insulin, and Cardiovascular Disease: Subgroup Analysis From the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT)

Rubins, H. B. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.22.2597 · Cited by 586 · see citing works

The apoB/apoA‐I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid‐lowering therapy – a review of the evidence

WALLDIUS, G., & JUNGNER, I. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01643.x · Cited by 583 · see citing works

Low-Density Lipoprotein and High-Density Lipoprotein Particle Subclasses Predict Coronary Events and Are Favorably Changed by Gemfibrozil Therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial

Otvos, J. D., Collins, D. E., Freedman, D. S., SHALAUROVA, I. Y., Schaefer, E. J., McNamara, J. R., Bloomfield, H. E., & Robins, S. J. (2006) · Circulation · doi:10.1161/circulationaha.105.565135 · Cited by 542 · see citing works

Importance of Different Pathways of Cellular Cholesterol Efflux

Yancey, P. G., Bortnick, A. E., Kellner-Weibel, G., de la Llera-Moya, M., Phillips, M. C., & Rothblat, G. H. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000057572.97137.dd · Cited by 506 · see citing works

Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds

Birjmohun, R. S., Hutten, B. A., Kastelein, J. J. P., & Stroes, E. S. G. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.10.031 · Cited by 429 · see citing works

Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S

Ballantyne, C. M., Olsson, A. G., Cook, T. J., Mercuri, M. F., Pedersen, T. R., & Kjekshus, J. (2001) · Circulation · doi:10.1161/hc5001.100624 · Cited by 416 · see citing works

Leukocyte ABCA1 controls susceptibility to atherosclerosis and macrophage recruitment into tissues

Van Eck, M., Bos, I. S. T., Kaminski, W. E., Orsó, E., Rothe, G., Twisk, J., Böttcher, A., Van Amersfoort, E. S., Christiansen-Weber, T. A., Fung-Leung, W.-P., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092327399 · Cited by 348 · see citing works

Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial)

Grundy, S. M., Vega, G. L., Yuan, Z., Battisti, W. P., Brady, W. E., & Palmisano, J. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.10.012 · Cited by 309 · see citing works

Roles of ATP binding cassette transporters A1 and G1, scavenger receptor BI and membrane lipid domains in cholesterol export from macrophages

Jessup, W., Gelissen, I. C., Gaus, K., & Kritharides, L. (2006) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000226116.35555.eb · Cited by 259 · see citing works

Postprandial lipemia. A key for the conversion of high density lipoprotein2 into high density lipoprotein3 by hepatic lipase.

Patsch, J. R., Prasad, S. C., Gotto, A. M., & Bengtsson-Olivecrona, G. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111624 · Cited by 256 · see citing works

Action of Atorvastatin in Combined Hyperlipidemia

Guérin, M., Lassel, T. S., Goff, W. L., Farnier, M., & Chapman, M. J. (2000) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.20.1.189 · Cited by 238 · see citing works

Effect of Simvastatin Therapy on Paraoxonase Activity and Related Lipoproteins in Familial Hypercholesterolemic Patients

Tomàs, M., Sentı́, M., García-Faria, F., Vila, J., Torrents, A., Covas, M. I., & Marrugat, J. (2000) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.20.9.2113 · Cited by 223 · see citing works

Triglycerides Are Major Determinants of Cholesterol Esterification/Transfer and HDL Remodeling in Human Plasma

Murakami, T., Michelagnoli, S., Longhi, R., Gianfranceschi, G., Pazzucconi, F., Calabresi, L., Sirtori, C. R., & Franceschini, G. (1995) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.15.11.1819 · Cited by 201 · see citing works

Fenofibrate Reduces Plasma Cholesteryl Ester Transfer From HDL to VLDL and Normalizes the Atherogenic, Dense LDL Profile in Combined Hyperlipidemia

Guérin, M., Bruckert, É., Dolphin, P. J., Turpin, G., & Chapman, M. J. (1996) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.16.6.763 · Cited by 194 · see citing works

Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT)

Ruotolo, G., Ericsson, C.-G., Tettamanti, C., Karpe, F., Grip, L., Svane, B., Nilsson, J. Å., Fairé, U. D., & Hamsten, A. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00442-2 · Cited by 158 · see citing works

An ω-3 polyunsaturated fatty acid concentrate increases plasma high-density lipoprotein 2 cholesterol and paraoxonase levels in patients with familial combined hyperlipidemia

Calabresi, L., Villa, B., Canavesi, M., Sirtori, C. R., James, R. W., Bernini, F., & Franceschini, G. (2004) · Metabolism · doi:10.1016/j.metabol.2003.09.007 · Cited by 132 · see citing works

Depletion of Pre-β-high Density Lipoprotein by Human Chymase Impairs ATP-binding Cassette Transporter A1- but Not Scavenger Receptor Class B Type I-mediated Lipid Efflux to High Density Lipoprotein

Favari, E., Lee, M., Calabresi, L., Franceschini, G., Zimetti, F., Bernini, F., & Kovanen, P. T. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312476200 · Cited by 122 · see citing works

Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS)

Klerkx, A. H. E. M., de Grooth, G. J., Zwinderman, A. H., Jukema, J. W., Kuivenhoven, J. A., & Kastelein, J. J. P. (2004) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2004.01281.x · Cited by 103 · see citing works

Scavenger Receptor Class B Type I-mediated Cholesteryl Ester-selective Uptake and Efflux of Unesterified Cholesterol

Thuahnai, S. T., Lund‐Katz, S., Dhanasekaran, P., de la Llera-Moya, M., Connelly, M. A., Williams, D. L., Rothblat, G. H., & Phillips, M. C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311718200 · Cited by 97 · see citing works

Lack of a Clinically Significant Pharmacokinetic Interaction between Fenofibrate and Pravastatin in Healthy Volunteers

Pan, W., Gustavson, L. E., Achari, R., Rieser, M. J., Ye, X., Gutterman, C., & Wallin, B. A. (2000) · The Journal of Clinical Pharmacology · doi:10.1177/00912700022008874 · Cited by 91 · see citing works

Associations Between Lipoproteins and the Progression of Coronary and Vein-Graft Atherosclerosis in a Controlled Trial With Gemfibrozil in Men With Low Baseline Levels of HDL Cholesterol

Syvänne, M., Nieminen, M. S., Frick, M. H., Kauma, H., Majahalme, S. K., Virtanen, V., Kesäniemi, Y. A., Pasternack, A. I., Ehnholm, C., & Taskinen, M. (1998) · Circulation · doi:10.1161/01.cir.98.19.1993 · Cited by 67 · see citing works

Human Apolipoproteins A-I and A-II in Cell Cholesterol Efflux

Chiesa, G., Parolini, C., Canavesi, M., Colombo, N., Sirtori, C. R., Fumagalli, R., Franceschini, G., & Bernini, F. (1998) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.18.9.1417 · Cited by 52 · see citing works

Effects of simvastatin on plasma lipoprotein subfractions, cholesterol esterification rate, and cholesteryl ester transfer protein in type II hyperlipoproteinemia

Homma, Y., Ozawa, H., Kobayashi, T., Yamaguchi, H., Sakane, H., & Nakamura, H. (1995) · Atherosclerosis · doi:10.1016/0021-9150(94)05487-4 · Cited by 51 · see citing works

Effects of lovastatin on ApoA- and ApoB-containing lipoproteins. Families in a subpopulation of patients participating in the Monitored Atherosclerosis Regression Study (MARS).

Alaupovic, P., Hodis, H. N., Knight‐Gibson, C., Mack, W. J., LaBree, L., Cashin-Hemphill, L., Corder, C. N., Kramsch, D. M., & Blankenhorn, D. H. (1994) · Arteriosclerosis and Thrombosis A Journal of Vascular Biology · doi:10.1161/01.atv.14.12.1906 · Cited by 48 · see citing works

Can change in high-density lipoprotein cholesterol levels reduce cardiovascular risk?

Dean, B. B., Borenstein, J. E., Henning, J. M., Knight, K., & Merz, C. N. B. (2004) · American Heart Journal · doi:10.1016/j.ahj.2003.10.051 · Cited by 47 · see citing works

Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia.

Franceschini, G., Sirtori, M., Vaccarino, V., Gianfranceschi, G., Chiesa, G., & Cr, S. (1989) · PubMed · Cited by 47 · see citing works

Comparison of Serum Lipid Values in Patients With Coronary Artery Disease at <50, 50 to 59, 60 to 69, and >70 Years of Age

da Luz, P. L., Cesena, F. Y., Favarato, D., & Cerqueira, E. S. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.07.080 · Cited by 45 · see citing works

Bezafibrate Increases Preβ1-HDL at the Expense of HDL 2b in Hypertriglyceridemia

Miida, T., Sakai, K., Ozaki, K., Nakamura, Y., Yamaguchi, T., Tsuda, T., Kashiwa, T., Murakami, T., Inano, K., & Okada, M. (2000) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.20.11.2428 · Cited by 37 · see citing works

Role of Lp A-I and Lp A-I/A-II in Cholesteryl Ester Transfer Protein–Mediated Neutral Lipid Transfer

McPherson, R., Agnani, G., Lau, P., Fruchart, J., Edgar, A. D., & Marcel, Y. L. (1996) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.16.11.1340 · Cited by 25 · see citing works

Effect of simvastatin on plasma lipids, apolipoproteins and lipoprotein particles in patients with primary hypercholesterolaemia

Bard, J., Luc, G., DOUSTE‐BLAZY, P., Drouin, P., Ziegler, O., JACOTOT, B., Dachet, C., Gennes, J. L. D., & Fruchart, J. (1989) · European Journal of Clinical Pharmacology · doi:10.1007/bf00562541 · Cited by 20 · see citing works

Structure of HDL: Particle Subclasses and Molecular Components

Kontush, A., Lindahl, M. G., Lhomme, M., Calabresi, L., Chapman, M. J., & Davidson, W. S. (2014) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-09665-0_1 · Cited by 284 · see citing works

Consumption of High-Oleic Acid Ground Beef Increases HDL-Cholesterol Concentration but Both High- and Low-Oleic Acid Ground Beef Decrease HDL Particle Diameter in Normocholesterolemic Men

Gilmore, L. A., Walzem, R. L., Crouse, S. F., Smith, D. R., Adams, T. H., Vaidyanathan, V., Cao, X., & Smith, S. B. (2011) · Journal of Nutrition · doi:10.3945/jn.110.136085 · Cited by 143 · see citing works

Characterization of Three Kindreds With Familial Combined Hypolipidemia Caused by Loss-of-Function Mutations of ANGPTL3

Pisciotta, L., Favari, E., Magnolo, L., Simonelli, S., Adorni, M. P., Sallo, R., Fancello, T., Zavaroni, I., Ardigò, D., Bernini, F., et al. (2011) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.111.960674 · Cited by 128 · see citing works

Antiatherogenic Functionality of High Density Lipoprotein: How Much versus How Gooden-subtitle=

Sviridov, D., Mukhamedova, N., Remaley, A. T., Chin-Dusting, J. P. F., & Nestel, P. J. (2008) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.e571 · Cited by 105 · see citing works

Dysfunctional high-density lipoproteins in coronary heart disease: implications for diagnostics and therapy

Annema, W., & von Eckardstein, A. (2016) · Translational Research · doi:10.1016/j.trsl.2016.02.008 · Cited by 94 · see citing works

Intracoronary Imaging, Cholesterol Efflux, and Transcriptomes After Intensive Statin Treatment

Kini, A. S., Vengrenyuk, Y., Shameer, K., Maehara, A., Meerarani, P., Yoshimura, T., Matsumura, M., Aquino, M. B., Haider, N., Johnson, K. W., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.10.029 · Cited by 90 · see citing works

Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence

Preiss, D., & Sattar, N. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03490.x · Cited by 92 · see citing works

Pharmacological Intervention to Modulate HDL: What Do We Target?

Woudberg, N. J., Pedretti, S., Lecour, S., Schulz, R., Vuilleumier, N., James, R. W., & Frias, M. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00989 · Cited by 77 · see citing works

Cholesterol efflux capacity: An introduction for clinicians

Anastasius, M. O., Kockx, M., Jessup, W., SULLIVAN, D. R., Rye, K., & Kritharides, L. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.07.005 · Cited by 76 · see citing works

Acquired lecithin:cholesterol acyltransferase deficiency as a major factor in lowering plasma HDL levels in chronic kidney disease

Calabresi, L., Simonelli, S., Conca, P., Busnach, G., Cabibbe, M., Gesualdo, L., Gigante, M., Penco, S., Veglia, F., & Franceschini, G. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12290 · Cited by 69 · see citing works

Effects of Increasing Exercise Intensity and Dose on Multiple Measures of HDL (High-Density Lipoprotein) Function

Sarzynski, M. A., Ruiz‐Ramie, J. J., Barber, J. L., Slentz, C. A., Apolzan, J. W., McGarrah, R. W., Harris, M. N., Church, T. S., Borja, M. S., He, Y., et al. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.310307 · Cited by 66 · see citing works

Effect of soy on metabolic syndrome and cardiovascular risk factors: a randomized controlled trial

Ruscica, M., Pavanello, C., Gandini, S., Gomaraschi, M., Vitali, C., Macchi, C., Morlotti, B., Aiello, G., Bosisio, R., Calabresi, L., et al. (2016) · European Journal of Nutrition · doi:10.1007/s00394-016-1333-7 · Cited by 65 · see citing works

Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid

Milionis, H. J., Moutzouri, E., Kei, & Elisaf, M. (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s5593 · Cited by 59 · see citing works

Inflammation impairs eNOS activation by HDL in patients with acute coronary syndrome

Gomaraschi, M., Ossoli, A., Favari, E., Adorni, M. P., Sinagra, G., Cattin, L., Veglia, F., Bernini, F., Franceschini, G., & Calabresi, L. (2013) · Cardiovascular Research · doi:10.1093/cvr/cvt169 · Cited by 54 · see citing works

Advanced glycation end-products (AGEs) and functionality of reverse cholesterol transport in patients with type 2 diabetes and in mouse models

Low, H., Hoang, A., Forbes, J. M., Thomas, M. C., Lyons, J. G., Nestel, P. J., Bach, L. A., & Sviridov, D. (2012) · Diabetologia · doi:10.1007/s00125-012-2570-9 · Cited by 52 · see citing works

Induction of Scavenger Receptor Class B Type I Is Critical for Simvastatin Enhancement of High-Density Lipoprotein-Induced Anti-Inflammatory Actions in Endothelial Cells

Kimura, T., Mogi, C., Tomura, H., Kuwabara, A., Im, D., Sato, K., Kurose, H., Murakami, M., & Okajima, F. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.10.7332 · Cited by 50 · see citing works

High-Density Lipoprotein Particles, Cell-Cholesterol Efflux, and Coronary Heart Disease Risk

Asztalos, B. F., Horvath, K. V., & Schaefer, E. J. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.311117 · Cited by 50 · see citing works

Simvastatin and bezafibrate increase cholesterol efflux in men with type 2 diabetes

Triolo, M., Annema, W., de Boer, J. F., Tietge, U. J. F., & Dullaart, R. P. F. (2013) · European Journal of Clinical Investigation · doi:10.1111/eci.12226 · Cited by 49 · see citing works

Modulating cholesterol efflux capacity to improve cardiovascular disease

Brownell, N. K., & Rohatgi, A. K. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000317 · Cited by 46 · see citing works

Recombinant LCAT (Lecithin:Cholesterol Acyltransferase) Rescues Defective HDL (High-Density Lipoprotein)-Mediated Endothelial Protection in Acute Coronary Syndrome

Ossoli, A., Simonelli, S., Varrenti, M., Morici, N., Oliva, F. G., Stucchi, M., Gomaraschi, M., Strazzella, A., Arnaboldi, L., Thomas, M. J., et al. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.311987 · Cited by 46 · see citing works

Dysfunctional HDL as a Therapeutic Target for Atherosclerosis Prevention

Ossoli, A., Pavanello, C., Giorgio, E., Calabresi, L., & Gomaraschi, M. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180316115726 · Cited by 45 · see citing works

Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients

Franceschini, G., Favari, E., Calabresi, L., Simonelli, S., Bondioli, A., Adorni, M. P., Zimetti, F., Gomaraschi, M., Coutant, K., Rossomanno, S., et al. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.06.007 · Cited by 43 · see citing works

Impaired Cholesterol Efflux Capacity of High-Density Lipoprotein Isolated From Interstitial Fluid in Type 2 Diabetes Mellitus—Brief Report

Apro, J., Tietge, U. J. F., Dikkers, A., Parini, P., Angelin, B., & Rudling, M. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.307385 · Cited by 43 · see citing works

High-Density Lipoprotein Functionality as a New Pharmacological Target on Cardiovascular Disease: Unifying Mechanism That Explains High-Density Lipoprotein Protection Toward the Progression of Atherosclerosis

Favari, E., Thomas, M. J., & Sorci‐Thomas, M. G. (2018) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000573 · Cited by 42 · see citing works

Fenofibrate and metabolic syndrome

T. Kraja, A., A. Province, M., J. Straka, R., M. Ordovas, J., B. Borecki, I., & K. Arnett, D. (2010) · Endocrine, Metabolic &amp; Immune Disorders - Drug Targets · doi:10.2174/187153010791213047 · Cited by 40 · see citing works

Novel concepts in HDL pharmacology.

Remaley, A., Norata, G., & Catapano, A. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu141 · Cited by 34 · see citing works

Effects of Established Hypolipidemic Drugs on HDL Concentration, Subclass Distribution, and Function

Gomaraschi, M., Adorni, M. P., Banach, M., Bernini, F., Franceschini, G., & Calabresi, L. (2014) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-09665-0_19 · Cited by 27 · see citing works

Apolipoprotein B-100 and apoA-II kinetics as determinants of cellular cholesterol efflux.

Chan, D. C., Hoang, A., Barrett, P. H., Wong, A. T. Y., Nestel, P. J., Sviridov, D., & Watts, G. F. (2012) · Journal of Clinical Endocrinology and Metabolism · doi:10.1210/jc.2012-1522 · Cited by 27 · see citing works

Understanding the heterogeneity and dysfunction of HDL in chronic kidney disease: insights from recent reviews

Xu, Z., Yang, S., & Cui, L. (2024) · BMC Nephrology · doi:10.1186/s12882-024-03808-3 · Cited by 27 · see citing works

HDL Structure

Deng, S., Xu, Y., & Zheng, L. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-1592-5_1 · Cited by 25 · see citing works

Optimal pharmacologic approach to patients with hypertriglyceridemia and low high-density lipoprotein-cholesterol: Randomized comparison of fenofibrate 160mg and niacin 1500mg

Wi, J. H., Kim, J., Park, S., Kang, S., Jang, Y., Chung, N., Shim, W., Cho, S.-Y., & Lee, S. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.08.068 · Cited by 23 · see citing works

Reverse cholesterol transport in type 2 diabetes mellitus

Tan, K. C. B. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.01012.x · Cited by 23 · see citing works

High-Density Lipoprotein Subclasses and Their Role in the Prevention and Treatment of Cardiovascular Disease: A Narrative Review

Chen, Q., Abudukeremu, A., Li, K., Zheng, M., Li, H., Huang, T., Huang, C., Wen, K., Wang, Y., & Zhang, Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147856 · Cited by 20 · see citing works

Effect of the amyloidogenic L75P apolipoprotein A-I variant on HDL subpopulations

Gomaraschi, M., Obici, L. P., Simonelli, S., Gregorini, G. A., Negrinelli, A., Merlini, G., Franceschini, G., & Calabresi, L. (2011) · Clinica Chimica Acta · doi:10.1016/j.cca.2011.03.027 · Cited by 20 · see citing works

The plasma concentration of Lpa-I:A-II particles as a predictor of the inflammatory response in patients with ST-elevation myocardial infarction

Gomaraschi, M., Sinagra, G., Serdoz, L. V., Pitzorno, C., Fonda, M., Cattin, L., Calabresi, L., & Franceschini, G. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.04.004 · Cited by 20 · see citing works

Cholesterol trafficking-related serum lipoprotein functions in children with cholesteryl ester storage disease

Zimetti, F., Favari, E., Cagliero, P., Adorni, M. P., Ronda, N., Bonardi, R., Gomaraschi, M., Calabresi, L., Bernini, F., & Guardamagna, O. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.08.007 · Cited by 19 · see citing works

Plasma Levels of Preβ1-HDL Are Significantly Elevated in Non-Dialyzed Patients with Advanced Stages of Chronic Kidney Disease

Kuchta, A., Ćwiklińska, A., Czaplińska, M., Wieczorek, E., Kortas‐Stempak, B., Gliwińska, A., Dąbkowski, K., Sałaga-Zaleska, K., Mickiewicz, A., Dębska-Ślizień, A. M., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051202 · Cited by 18 · see citing works

Simultaneous co-assembly of fenofibrate and ketoprofen peptide for the dual-targeted treatment of nonalcoholic fatty liver disease (NAFLD)

Wang, Z., Ma, C., Shang, Y., Yang, L., Zhang, J., Yang, C., Ren, C., Liu, J., Fan, G., & Liu, J. (2020) · Chemical Communications · doi:10.1039/d0cc00513d · Cited by 18 · see citing works

Environmental Factors Modifying HDL Functionality

Kostara, C. E., Kosmas, C. E., Sourlas, A., & Guzman, E. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210714155422 · Cited by 17 · see citing works

Drug Class Review: HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin

Smith, M. B., Lee, E., Haney, E. M., & Carson, S. (2009) · Cited by 17 · see citing works

Plasma HDL pattern, cholesterol efflux and cholesterol loading capacity of serum in carriers of a novel missense variant (Gly176Trp) of endothelial lipase

Pisciotta, L., Ossoli, A., Ronca, A., Garuti, A., Fresa, R., Favari, E., Calabresi, L., Calandra, S., & Bertolini, S. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.08.002 · Cited by 13 · see citing works

Abdominal obesity negatively influences key metrics of reverse cholesterol transport

Härdfeldt, J., Cariello, M., Simonelli, S., Ossoli, A., Scialpi, N., Piglionica, M., Pasculli, E., Noia, A., Berardi, E., Suppressa, P., et al. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2021.159087 · Cited by 13 · see citing works

The Differential Effects of HDL Subpopulations on Lipoprotein Lipase (LPL)-Mediated VLDL Catabolism

Wieczorek, E., Ćwiklińska, A., Kuchta, A., Kortas‐Stempak, B., Gliwińska, A., & Jankowski, M. (2021) · Biomedicines · doi:10.3390/biomedicines9121839 · Cited by 14 · see citing works

HDL subpopulations containing apoA-I without apoA-II (LpA-I) in patients with angiographically proven coronary artery disease

Kuchta, A., Strzelecki, A., Ćwiklińska, A., Gruchała, M., Zdrojewski, Z., Kortas‐Stempak, B., Wieczorek, E., Gliwińska, A., Dąbkowski, K., & Jankowski, M. (2016) · Journal of Cardiology · doi:10.1016/j.jjcc.2016.04.007 · Cited by 13 · see citing works

Fibrate treatment induced quantitative and qualitative HDL changes associated with an increase of SR-BI cholesterol efflux capacities in rabbits

Fournier, N., Tuloup-Minguez, V., Pourci, M. L., Thérond, P., Jullian, J., Wien, F., Leroy, M., Dallongeville, J., Paul, J., & Leroy, A. (2013) · Biochimie · doi:10.1016/j.biochi.2013.02.001 · Cited by 11 · see citing works

High density lipoprotein as a therapeutic target: Focus on its functionality

Rosso, L. A. G., Davico, B., Chiappe, E. L., Tetzlaff, W., Boero, L. E., Brites, F. D., & Martín, M. (2023) · Biocell · doi:10.32604/biocell.2023.031063 · Cited by 10 · see citing works

Aspirin Increases Apolipoprotein-A-I-Mediated Cholesterol Efflux via Enhancing Expression of ATP-Binding Cassette Transporter A1

Wang, Y., Chen, Y., Chen, S., Chen, X., Chen, J., Shen, X., Mou, Y., & Liu, P. (2010) · Pharmacology · doi:10.1159/000321727 · Cited by 10 · see citing works

High-Density Lipoprotein Subfractions Remodeling: A Critical Process for the Treatment of Atherosclerotic Cardiovascular Diseases

Zhang, Y., Luo, S., Gao, Y. Q., Tong, W., & Sun, S. (2023) · Angiology · doi:10.1177/00033197231157473 · Cited by 9 · see citing works

A review of paradoxical HDL-C responses to fenofibrate, illustrated by a case report

Schofield, J. D., Liu, Y., France, M. W., Sandle, L. N., & Soran, H. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.05.003 · Cited by 8 · see citing works

Hyperlipidemia and cardiovascular disease: cardiovascular update

Le, N. (2008) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32830f4a57 · Cited by 8 · see citing works

A complex phenotype in a child with familial HDL deficiency due to a novel frameshift mutation in APOA1 gene (apoA-I Guastalla )

Pisciotta, L., Vitali, C., Favari, E., Fossa, P., Adorni, M. P., Leone, D., Artom, N., Fresa, R., Calabresi, L., Calandra, S., et al. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.09.001 · Cited by 7 · see citing works

Advanced diagnostic support in lipidology project: role for phenotypic and functional evaluation of lipoproteins in dyslipidemias

Ardigò, D., Bernini, F., Borghi, C., Calandra, S., Cicero, A. F. G., Favari, E., Fellin, R., Franzini, L., Vigna, G. B., Zimetti, F., et al. (2010) · Clinical Lipidology · doi:10.2217/clp.10.20 · Cited by 7 · see citing works

Novel missense variants in LCAT and APOB genes in an Italian kindred with familial lecithin:cholesterol acyltransferase deficiency and hypobetalipoproteinemia

Conca, P., Pileggi, S., Simonelli, S., Boer, E., Boscutti, G., Magnolo, L., Tarugi, P., Penco, S., Franceschini, G., Calabresi, L., et al. (2012) · Journal of clinical lipidology · doi:10.1016/j.jacl.2012.01.006 · Cited by 6 · see citing works

Paradoxical Decrease in High‐Density Lipoprotein Cholesterol with Fenofibrate: A Quite Rare Phenomenon Indeed

Mombelli, G. G., Pazzucconi, F., Bondioli, A., Zanaboni, A., Gaito, S., Calabresi, L., & Sirtori, C. R. (2010) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2009.00121.x · Cited by 6 · see citing works

Effects of pitavastatin on HDL metabolism

Kishida, K., Funahashi, T., & Shimomura, I. (2013) · Clinical Lipidology · doi:10.2217/clp.12.87 · Cited by 3 · see citing works

Drug Evaluation: The Combination of Fenofibrate and Simvastatin for the Treatment of Dyslipidemia: When and for Whom?

Nikolić, D., Katsiki, N., Toth, P. P., Banach, M., Al-Waili, K., Al‐Rasadi, K., Rizzo, M., & Mikhailidis, D. P. (2015) · Springer eBooks · doi:10.1007/978-3-319-20433-8_15 · Cited by 2 · see citing works

Established and Emerging Approaches for the Management of Dyslipidaemia

Norata, G. D. (2012) · Scientifica · doi:10.6064/2012/482423 · Cited by 2 · see citing works

Comparing the effect of lovastatin and exercise on serum lipid profile in hyperlipidaemic patients

Taghadosi, M., Fath-Gharib, B. J., & Piroozmand, A. (2013) · International Journal of Medicine and Biomedical Research · doi:10.14194/ijmbr.214 · Cited by 2 · see citing works

Therapies Targeting HDLc Levels and HDL Function

Vitali, C., & Cuchel, M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-812513-7.00012-4 · Cited by 1 · see citing works

Comparative study of the effect of atorvastatin and fenofibrate on high-density lipoprotein cholesterol levels in patients with type 2 diabetes

Najafipour, F., Najafipour, M., Zareizadeh, M., & Khokhi, M. (2018) · Journal of Advanced Pharmaceutical Technology amp Research · doi:10.4103/japtr.japtr_314_18 · Cited by 1 · see citing works

Humoral response towards high density lipoprotein : a new mechanism for atherogenesis

Batuca, J. R. (2013) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · Cited by 1 · see citing works

Enhancement of HDL Formation and Normalization of Intravascular HDL Remodeling

Kontush, A., & Chapman, M. J. (2011) · Wiley eBooks · doi:10.1002/9781118158678.ch11

A survey on the effect of lovastatin and exercise on serum lipid profiles in hyperlipidemic patients

Taghadosi, M., Seyedy, M., Mousavi, S. G. A., & Fathgharib, J. (2009) · KAUMS Journal

Fibrate Therapy: Impact on Dyslipidemia and Cardiovascular Events in Diabetic Patients

Brinton, E. A. (2013) · Contemporary diabetes · doi:10.1007/978-1-4614-7554-5_20

Author Index

(2007) · Atherosclerosis · doi:10.1016/s0021-9150(07)00702-2

Fibrate Therapy: Impact on Dyslipidemia and Cardiovascular Events in Patients with Diabetes Mellitus Type 2

Brinton, E. A., & Pulipati, V. P. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_24

Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome

Vega, G. L., Ma, P. T. S., Cater, N. B., Filipchuk, N. G., Meguro, S., García-García, A.-B., & Grundy, S. M. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00111-5 · Cited by 149 · see citing works

Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles

Wang, T.-D., Chen, W.-J., Lin, J.-W., Cheng, C.-C., Chen, M.-F., & Lee, Y.-T. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(03)00296-x · Cited by 125 · see citing works

A comparison of fenofibrate and statins in raising low HDL-C

Delaval, D. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(00)80613-9

Effects of micronized fenofibrate versus atorvastatin in the treatment of dyslipidaemic patients with low plasma HDL‐cholesterol levels: a 12‐week randomized trial

Despres, J., Lemieux, I., Salomon, H., & Delaval, D. (2002) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2002.00988.x · Cited by 49 · see citing works

New Fixed‐Dose Combinations of Fenofibrate/Simvastatin Therapy Significantly Improve the Lipid Profile of High‐Risk Patients with Mixed Dyslipidemia Versus Monotherapies

Foucher, C., Aubonnet, P., Reichert, P., Berli, M. A., Schaeffer, A., Vargas, C. G. C., Lochocka, A., Belenky, D., Koch, H., & the Cholib study Investigators (2015) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12148 · Cited by 12 · see citing works